Country for PR: United Kingdom
Contributor: PR Newswire Europe
Monday, February 17 2020 - 20:00
A New Expert Consensus Publication Provides Practical Guidance on the Use of Omega-3 Fatty Acids in Parenteral Nutrition
BAD HOMBURG, Germany, Feb. 17, 2020 /PRNewswire-AsiaNet/--

Fresenius Kabi, a global leader in clinical nutrition, announces that the 
Journal of Parenteral and Enteral Nutrition (JPEN) has recently published 
"Lipids in Parenteral Nutrition: Translating Guidelines into Clinical 
Practice".[1] The publication represents the largest set of expert consensus 
statements to provide guidance on the use of fish oil-containing lipid 
emulsions in clinical practice.   

An international panel of leading experts in clinical nutrition, lipid 
metabolism, and pharmacology developed a set of 43 consensus recommendations. 
The recommendations aim to help healthcare professionals to navigate issues 
around prescription, administration, safety, and monitoring of lipids - from 
short- to long-term parenteral nutrition, from pediatric to adult patients, 
from home to hospital care.

Fish oil-containing parenteral nutrition has been shown to have a variety of 
beneficial effects on key biological functions, including modulation of the 
immune and inflammatory response. A growing body of evidence suggests that 
these properties improve clinical outcomes, e.g. infection rates, sepsis rate, 
length of ICU and hospital stay.[2] 

Current guidelines of international clinical societies recommend the use of 
fish oil-containing lipid emulsions in parenteral nutrition.[3-5] Regarding 
specific nutrients, only parenteral lipid emulsions with EPA + DHA* are 
recommended by the European Society for Clinical Nutrition and Metabolism 
(ESPEN) guideline on clinical nutrition in the intensive care unit.[4] 

To read the summary of consensus statements along with the review of current 
evidence on the clinical benefits of omega-3 fatty acids in parenteral 
nutrition across the healthcare continuum, visit 

Register now for the free 2-part educational series offered by the American 
Society for Parenteral and Enteral Nutrition (ASPEN) specifically on this 
topic: "Expert Consensus on Omega-3 Fatty Acids in Parenteral Nutrition:  Focus 
on Critical Care and Major Surgery" on April 22, 2020, and "Expert Consensus on 
Omega-3 Fatty Acids in Parenteral Nutrition:  Continuum of Care - From Hospital 
to Home Care" on July 9, 2020. Visit the ASPEN Clinical Nutrition Webinar 
Series at

* EPA=eicosapentaenoic acid; DHA=docosahexanoic acid


1. Martindale R, Berlana D, Boullata J, et al. Lipids in Parenteral Nutrition: 
Translating Guidelines into Clinical Practice. JPEN J Parenter Enteral Nutr. 
2020;44(suppl S1):S1-S84. 
2. Pradelli L, Mayer K, Klek S et al. omega 3 Fatty-Acid Enriched Parenteral 
Nutrition in Hospitalized Patients: Systematic Review With Meta-Analysis and 
Trial Sequential Analysis. JPEN J Parenter Enteral Nutr. 2020;44(1):44-57. 
3. McClave SA, Taylor BE, Martindale RG et al. Guidelines for the Provision and 
Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: 
Society of Critical Care Medicine (SCCM) and American Society for Parenteral 
and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 
2016;40(2):159 - 211. 
4. Singer P, Blaser AR, Berger MM et al. ESPEN guideline on clinical nutrition 
in the intensive care unit. Clin Nutr. 2019;38(1):48 - 79. 5. Lapillonne A, 
Fidler Mis N, Goulet O et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric 
parenteral nutrition: Lipids. Clin Nutr. 2018;37(6 Pt B):2324-36.

About Fresenius Kabi

Fresenius Kabi is a global healthcare company that specializes in lifesaving 
medicines and technologies for infusion, transfusion and clinical nutrition. 
The company's products and services are used to help care for critically and 
chronically ill patients. Fresenius Kabi's product portfolio comprises a 
comprehensive range of I.V. generic drugs, infusion therapies and clinical 
nutrition products as well as the devices for administering these products. In 
the field of biosimilars, we focus on autoimmune diseases and oncology. In 
2019, the first biosimilar product by Fresenius Kabi was launched. Within 
transfusion medicine and cell therapies, Fresenius Kabi offers products for 
collection and processing of blood and cell components. 

With its corporate philosophy of "caring for life", the company is committed to 
putting essential medicines and technologies in the hands of people who help 
patients and finding the best answers to the challenges they face. 

For more information, please visit: 

For press inquiries, please contact:   
Nina Espiritu    
Edelman GmbH   
Barmbeker Str 4, 22303 Hamburg, Germany    
T: +49-(0)69-401254-345 

SOURCE: Fresenius Kabi Deutschland GmbH